FDA Clears New Sizes Of Resolute Integrity Coronary Stent For Long Lesions Common Among Diabetes Patients

In short

Medtronic, Inc. has announced that the U.S. FDA has approved the 34mm and 38mm lengths of the Resolute Integrity drug-eluting stent in diameters of 3.0mm, 3.5mm and 4.0mm, including an indication for patients with diabetes.


Like the core sizes approved by the FDA in February 2012, the 34mm and 38mm lengths of the Resolute Integrity stent are uniquely indicated for treating the coronary artery disease of patients with diabetes, who commonly present with long lesions.

FDA approval of the 34mm and 38mm lengths of the Resolute Integrity stent is based on data from the global RESOLUTE clinical program –– specifically, a pre-specified analysis of one-year outcomes in patients with long coronary lesions.

The analysis included data on 222 patients who received a 38mm Resolute stent for the treatment of coronary lesions of no greater than 35mm in length. The primary endpoint for the analysis was target lesion failure (TLF) –– a composite of cardiac death, target vessel myocardial infarction and clinically-driven target lesion revascularization (TLR) –– at one year of follow-up.

The long-lesion analysis met its primary endpoint, with a one-year TLF rate of 4.5 percent. Among the 38 percent of patients with diabetes, the one-year TLF rate was similarly low at 6.0 percent. The one-year rates of clinically driven TLR for all patients and the subset of diabetes patients were 1.4 percent and 2.4 percent, respectively.

Physician comments

“Long coronary lesions and diabetes represent two distinct but often interrelated clinical challenges,” said Ronald Caputo, M.D., director of cardiac services and cardiology research at St. Joseph’s Hospital in Syracuse, N.Y. “The new sizes of the Resolute Integrity drug-eluting stent address both challenges in a single device. They have the potential to reduce procedure time and cost for clinicians and hospitals, as well as vessel trauma and contrast exposure for patients.”

Source: Medtronic, Inc.